Primary Immunoglobulin A Nephropathy — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for primary immunoglobulin a nephropathy. 37 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
37
Active US patents
68/100
Avg vulnerability
$2.8B
Annual revenue covered

Originators in Primary Immunoglobulin A Nephropathy

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

AstraZeneca K.K. 37 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating primary immunoglobulin a nephropathy. Each bar = one year. Y-axis scaled to peak year (8 patents).

6
26
2
28
3
29
8
30
6
31
4
36
2
38
2
39

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Pulmicort Respules
BUDESONIDE
 AstraZeneca K.K. 37 68 $2.8B 2026-11-09

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9119863 Pulmicort Respules method of use 93 2026-11-09
8497258 Pulmicort Respules method of use 93 2026-11-09
8975243 Pulmicort Respules method of use 93 2026-11-09
11357859 Pulmicort Respules method of use 88 2028-11-12
8491932 Pulmicort Respules method of use 83 2029-05-07
8324192 Pulmicort Respules method of use 81 2029-08-03
9415009 Pulmicort Respules method of use 76 2030-05-28
10716753 Pulmicort Respules method of use 76 2030-05-28
11564934 Pulmicort Respules method of use 75 2039-01-10
11896719 Pulmicort Respules method of use 75 2043-01-23

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10307375 Pulmicort Respules formulation 48 2031-09-07
9132093 Pulmicort Respules formulation 48 2031-09-07
10660858 Pulmicort Respules formulation 48 2031-09-07
11331442 Pulmicort Respules formulation 50 2038-10-05
11833292 Pulmicort Respules formulation 50 2038-10-05
8895064 Pulmicort Respules formulation 53 2031-09-07
12171883 Pulmicort Respules formulation 55 2043-01-23
11260064 Pulmicort Respules formulation 55 2039-01-10
9050368 Pulmicort Respules formulation 61 2029-08-01
10172802 Pulmicort Respules method of use 62 2036-09-09

Related